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Abstract
Introduction: Levels of cerebrospinal fluid (CSF) b-amyloid (Ab) and Tau proteins change in Alzheimer’s disease
(AD). We tested if the relationships of these biomarkers with cognitive impairment are linear or non-linear.
Methods: We assessed cognitive function and assayed CSF Ab and Tau biomarkers in 95 non-demented
volunteers and 97 AD patients. We then tested non-linearities in their inter-relations.
Results: CSF biomarkers related to cognitive function in the non-demented range of cognition, but these relations
were weak or absent in the patient range; Ab1-40’s relationship was biphasic.
Conclusions: Major biomarker changes precede clinical AD and index cognitive impairment in AD poorly, if at all.
Introduction
The incidence and prevalence of Alzheimer’s disease
(AD) double every five years from age 65, to affect over
one quarter of people aged over 85 [1,2]. AD pathology
can develop long before clinical symptoms [3-5]. This
means that, ideally, disease-modifying treatments should
begin before diagnosis [6]. Consequently, there is much
interest in finding biomarkers that can predict the onset
of AD [7]. There is also much interest in finding bio-
markers to assess treatment effects [8]. Leading candi-
dates for these roles are b-amyloid (Ab)a n dT a u
proteins in the cerebrospinal fluid (CSF) [9-15]. To date,
nearly all studies of CSF biomarkers have related them
to diagnostic categories -AD and mild cognitive impair-
ment (MCI). However, the boundaries of diagnostic
categories, particularly MCI, are uncertain [16-18]. We,
therefore, related CSF biomarkers directly to cognitive
test scores.
The form of the relationship between biomarker levels
and cognitive scores is important. To predict the onset
of AD, a biomarker should relate to cognitive decline
pre-clinically. Conversely, to monitor disease progres-
sion and treatment response, a biomarker should relate
to cognitive level in the range of clinical dementia.
These relationships may be such that alterations in bio-
marker expression may precede, coincide with, or lag
behind changes in cognitive status. The simplest
assumption would be that the relation of CSF amyloid
and Tau biomarkers with cognitive function is linear
from cognitive normality through MCI to AD. If so,
then these biomarkers might be useful for both the pre-
diction of AD and monitoring its progression. However,
most studies that related CSF Ab and Tau levels to cog-
nitive scores [9,19,20] did not test this assumption of a
linear relationship and one study [21] found no relation-
ship in AD patients. Moreover, recent studies that used
diagnostic categories have provided evidence of biphasic
changes in levels of putative biomarkers between con-
trols, MCI and AD patients in CSF [21,22] and blood
[23,24]. These findings support Combrinck’sh y p o t h e s i s
[25] that biomarkers may relate non-linearly to cognitive
function. Here, we test this hypothesis further by analys-
ing the forms of the relations between CSF biomarkers
and cognitive scores.
We have previously reporte dab i p h a s i cr e l a t i o n
between CSF PGE2 levels and cognitive scores, using an
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present study uses change-point analyses with highly
robust linear regression to test for non-linearity in
cross-sectional relations between cognitive scores and
CSF Ab and Tau moieties.
Materials and methods
Participants
Participants were volunteers in the Oxford Project To
Investigate Memory and Ageing (OPTIMA), a naturalis-
tic longitudinal study of memory and ageing. All OPTI-
MA’s protocols received prior ethical approval from the
local research ethics committee (COREC #1656).
OPTIMA is a convenience sample of patients with
dementia and non-demented volunteers of similar age.
We have described OPTIMA’s recruitment and assess-
ment protocol previously [26]. Briefly, at their initial
assessment all participants underwent a physical exami-
nation, blood tests, CT scan and cognitive assessment
using the Cambridge Cognitive examination (CAM-
COG) [27]. We also obtained a detailed history from
participants and an informant. We invited participants
who could give valid consent to undergo a lumbar
puncture (LP).
Clinical diagnoses of Alzheimer’s disease or Other
Dementia Syndromes used the National Institute of
Neurological and Communicative Disorders and Stroke
(NINCDS) criteria [28]. OPTIMA has a high rate of
autopsy acceptance (over 80%). Details of OPTIMA’s
neuropathological examinations are available elsewhere
[29]. We supplanted clinical diagnoses whenever possi-
ble by neuropathological diagnoses using Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD)
criteria [30]. The present analysis did not include con-
sideration of Braak staging [3] in the determination of
neuropathological diagnosis or its relationship to the
variables studied.
The present report includes data from all non-demen-
ted controls and AD patients aged over 60 who under-
went lumbar puncture and whose CAMCOG data were
complete. It excludes patients with clinical or neuro-
pathological diagnoses of non-Alzheimer dementias.
Lumbar punctures
All LPs used standard clinical techniques [31]. Most
took place in the late morning. LP has a low risk of
adverse effects in our cohort [31]. We collected the CSF
samples into polystyrene tubes.
CSF assays
We centrifuged CSF samples for 10 minutes at 4°C at
1,000 g to remove cells and stored the supernatant in
aliquots of 0.5 ml in polypropylene tubes at -70°C. We
assayed levels of CSF Ab and Tau moieties using
commercial kits. No sample underwent any freeze-thaw
cycles between collection and these assays.
Ab1-40 assay
Ab1-40 was measured in the CSF with a human Ab1-40
Colorimetric solid phase sandwich Enzyme Linked
Immuno-Sorbent Assay (ELISA) kit (catalogue #
KHB3482, BioSource International, Camarillo, CA, USA)
following the manufacturer’s recommendations. This
assay employs a mouse monoclonal antibody specific for
the N-terminal half of Ab1-40 as capture and a rabbit
anti- Ab1-40 neo-epitope (secondary antibody). The
detection antibody consisted of a secondary anti-rabbit
IgG:horse radish peroxidase (HRP) conjugate. HRP cata-
lyzes the formation of a chromophore, tetramethylbenzi-
dine (TMB), which was measured at 450 nm. A total of
100 μLo ft h es a m p l e( C S Fd i l u t e d1 : 2 0i na s s a yb u f f e r )
was used in this assay. The standards were provided in
t h eB i o S o u r c ea s s a yk i ta n dt h e yr a n g e df r o m1 5 . 6t o
1000 pg/mL.
Ab1-42 assay
Ab1-42 was measured with Innotest™ Ab1-42 ELISA kit
(Innogenetics Inc., Cat. #80040, Ghent, Belgium) follow-
ing the manufacturer’s recommendations with some
modifications. Ab1-42 present in human CSF samples
was first captured with a mouse monoclonal antibody
specific for the C-terminal half of Ab The detection sys-
tem employs an N-terminal specific biotinylated mouse
monoclonal antibody and a secondary conjugate made
of HRP labeled strepavidin. The HRP is used to convert
tetramethyl benzidine to a chromophore which is quan-
titatively measured at 450 nm. A total of 100 μLo ft h e
sample (CSF Diluted 1:3 with Sample Diluent) was used
in each reaction. Ab1-42 standard was purchased from
American Peptide (Sunnyvale, CA, USA) and the con-
centration was determined by amino-acid analysis. Stan-
dard concentrations in the assay ranged from 5.45 to
350 pg/mL.
Tau assay
Total Tau (t-Tau) expression was measured with a
human Tau (hTAU AG Innotest™) ELISA kit (Innoge-
netics Inc., catalogue number 80226, Ghent, Belgium)
following the manufacturer’s recommendations. The
analyte was first captured with a monoclonal antibody
specific for all isoforms of Tau, and then subsequently
bound by two biotinylated Tau-specific antibodies. The
final detection was performed by peroxidase-labeled
streptavidin. A total of 25 μL of the sample was tested
undiluted. The standards were supplied with the kit and
ranged from 37.5 to 1200 pg/mL.
Phospho-Tau assay
Phosphorylated Tau-181 (pTau-181) was measured with
the Phospho-TAU (181P)I n n o t e s t ™ ELISA kit (Innoge-
netics Inc., catalogue number 80062, Ghent, Belgium),
following the manufacturer’s recommendations.
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Page 2 of 11The analyte was first captured with an antibody specific
for all isoforms of Tau and then detected with a second
detection antibody which specifically detects Tau mole-
cules phosphorylated at threonine 181 (phospho-tau-
181). A 75 μL sample was tested undiluted. The
standards were supplied with the kit and ranged from
15.6 to 500 pg/mL.
Assay validation
All assays were analytically validated (inter- and intra-
assay precision, freeze/thaw stability, linearity, spike
recovery, and sensitivity). In addition, quality control
samples (low, medium, and high) were run on all plates
and were used as part of the run acceptance criteria. All
analytes were found to be stable (<20% change) after
three freeze-thaw cycles. All sample analyses were per-
formed in duplicate.
For the Ab1-40 assay, the intra- and inter-assay percent
coefficient of variation (% CV) ranged from 4.1% to
7.6% and 9.4% to 12.5%, respectively. The spike recovery
was determined to be 105 to 114% and the lower limit
of reliable quantitation was 17.8 pg/mL.
For the Ab1-42 assay, the intra- and inter-assay % CV
ranged from 3.7 to 4.7% and 5.9 to 7.6%, respectively.
The spike recovery was determined to be 70 to 109%
and the lower limit of reliable quantitation was
24.5 pg/mL.
F o rt h et - T a ua s s a y ,t h ei n t r a -a n di n t e r - a s s a y%C V
ranged from 3.8 to 9.0% and 6.2 to 7.2%, respectively.
The spike recovery was determined to be 105 to 116%
and the lower limit of detection was 37.5 pg/mL.
For the p-Tau assay, the intra- and inter-assay % CV
ranged from 1.3 to 2.2% and from 4.9 to 5.3%, respec-
tively. The spike recovery was determined to be 84 to
89% and the lower limit of detection was 15.6 pg/mL.
Statistics
All statistical analyses used the open-source statistical
programming language ‘R’ [32]. We used the Wilcoxon-
Mann-Whitney signed rank test and Pearson’s c
2 to
compare the demographic characteristics of the patient
and non-demented groups.
We first performed omnibus tests for non-linearity using
multivariate analysis of variance (MANOVA) [33]. The
first MANOVA tested the dependence of all four biomar-
kers on age, gender, storage time, CAMCOG score and
assay group. A second MANOVA included all the above
variables and a second CAMCOG term representing an
inflection in the relationship with cognitive function, cor-
responding with our previous work [25]. That study
showed an inflection in the relation between CSF PGE2
levels and CAMCOG learning sub-scale scores at a score
of 11, the lowest limit of the non-demented range. In the
present study, we first ascertained the total CAMCOG
score that corresponded best with a CAMCOG learning
sub-scale score of 11, then programmed an inflection at
that total score (89).
The strategy of pre-defining an inflection point for all
CSF biomarkers may be sub-optimal if different biomar-
kers show different inflection points. Therefore, having
obtained evidence of a significant inflection in our
MANOVA (see Results), we tested for change-points in
the relations between each individual biomarker level
and CAMCOG score. These change-point analyses were
of two kinds. First, we tested for changes in the overall
level of each biomarker in relation to CAMCOG. These
analyses used the “Fstats” and “breakpoints” procedures
for testing structural changes in linear regression models
[34]. Second, we tested for change-points in the slope of
the relation between each biomarker and CAMCOG.
These analyses used the “linearSegmentation” procedure
for piecewise linear segmentation of a time series [35].
This procedure requires data in a continuous equally-
spaced series with one observation at each point. We
converted the CAMCOG scores to a series of this kind
by ranking them and randomly splitting ties. Since the
order of the random splits may affect the result of the
change-point analysis, we repeated the analysis 1,000
times with a different random seed to split ties in each
repetition. Each analysis progressively increased the win-
dow size and tolerance angle in each repetition, until
the procedure generated a single change-point for each
biomarker. We recorded the change-points for each bio-
marker in each of the 1000 repetitions. Finally, we
extracted the median of these 1000 estimates. Hence,
for each biomarker we derived two change-points:
1) CAMCOG scores at which the biomarker changed its
level, and 2) change in the slope of the relation between
each biomarker and CAMCOG. These two change-
points were very similar for each biomarker, so we used
their mean in further analyses.
We assessed the validity of the change-point for each
biomarker in three ways. First, we visually compared the
change-point and model-free robust Lowess fits (Figures 1,
2, 3, 4). Second, we compared the variances and medians
of each biomarker on each side of its change-point using
simple variance ratios and Wilcoxon-Mann-Whitney
(WMW) tests. Third, we compared the relationship of the
biomarker with CAMCOG on each side of its change-
point using Spearman’s r and robust linear modelling
(rlm) [36]. The rlms used highly robust M-estimation (via
the ‘MM’ option) with a breakdown point of 0.5 and 95%
relative efficiency at the normal.
Results
Participants
A total of 192 participants fulfilled the inclusion criteria;
97 received a diagnosis of AD and 25 of the non-
demented volunteers received a designation of MCI.
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Page 3 of 11We obtained post mortem neuropathological confirma-
tion of the diagnosis in 90% of the AD patients (88/97)
and a third of the non-demented goup (30/95). All par-
ticipants were white West Europeans. Table 1 shows
their demographic and clinical characteristics. The age
and gender distributions of the non-demented partici-
pants and AD patients did not differ (age: WMW P =
0.11; gender: Fisher exact P =0 . 1 5 ) .C o m p a r e dw i t h
non-demented participants, AD patients had lower
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Figure 1 The dependence of CSF Ab1-40 levels (y-axis) on
CAMCOG score (x-axis), which decreases from left to right, as
cognitive impairment increases. The Figure represents the fits of
four different models to the data. (1) The horizontal blue dot-dash
lines represent the means for each diagnostic category. (2) The
straight green dotted line represents a robust linear regression of
CSF Ab1-40 levels on CAMCOG score that does not include the
change point. (3) The solid black lines represent the robust
regression model that takes into account the change point (vertical
dashed line). (4) The curvilinear dashed red line is the model-free
robust locally-fitted Lowess line. Closed circles represent cognitively
healthy participants and open squares represent patients with AD.
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Figure 2 The dependence of CSF Ab1-42 levels on CAMCOG
score. All details as for Figure 1.
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Figure 3 The dependence of CSF Tau levels on CAMCOG score.
All details as for Figure 1.
●
●
●
●
● ●
●
● ●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
● ● ●
●
● ●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
● ● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
● ●
●
●
●
●
●
5
0
1
0
0
1
5
0
2
0
0
cognitive impairment (CAMCOG score)
P
−
τ
1 0 0 8 06 04 02 0 0
●
●
●
●
● ●
●
●
●
● ●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
● ●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
type of fit
diagnostic category
linear regression
change−point model
robust Lowess line
Figure 4 The dependence of CSF phospho-Tau levels on
CAMCOG score. All details as for Figure 1.
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Page 4 of 11MMSE and CAMCOG scores and shorter follow-up (all
WMW P-values < 0.001). We have provided further
clinical details in Additional file 1. The role of the diag-
nostic procedures in the present study was to ensure
that the study group did not include participants with
non-Alzheimer dementias. Therefore, neither clinical
nor neuropathological diagnostic categorisations played
any part in the design or interpretation of our change-
point analyses, which concern only the forms of the
relations between CSF biomarkers and CAMCOG
scores.
Multivariate inflection model
The inflection point in the total CAMCOG score corre-
sponding to our previous finding [an inflection at a
CAMCOG learning sub-scale score of 11 - see 25] was
89. Biomarker levels showed different levels and their
relations with CAMCOG scores showed different slopes
above and below total scores of 89 (levels: F = 11.5,
4/167 df, P < 0.0001. Slopes: F = 3.31, 4/167 df, P =
0.012) (see Table 2 and Figures 1, 2, 3, 4).
CSF Ab1-40
CSF Ab1-40 levels showed biphasic dependence on
CAMCOG scores, with the change-point at a CAMCOG
of 90 (Figure 1). The change-point model fitted the data
better than the simpler linear model (F = 3.27, 2/187df,
P =0 . 0 4 ) .T h e r ew a sap o sitive relation of Ab1-40 with
CAMCOG scores above the change point (rlm: t = 2.65,
187 df, P = 0.009) but a negative relation below it (rlm:
t = -3.25, 187 df, P = 0.001; Table 2). Congruent with
this, the Spearman’s rs on each side of the change-point
were opposite in sign and both differed from zero
(Table 2; Figure 1). The median and variance of Ab1-40
levels were greater above the change-point than below it
(median: WMW P < 0.001; variance: F = 1.95; 96/96 df;
P < 0.0001; see Table 2). In summary, the levels and
variability of CSF Ab1t o0and the sign of its relation
with CAMCOG differed above and below the change-
point.
CSF Ab1-42
CSF Ab1-42 levels showed monotonic but non-linear
dependence on CAMCOG scores with the change-point
at a CAMCOG of 90 (Figure 1b). The change-point model
fitted better than the simpler linear model (F = 11.2, 2/178
df, P < 0.001). There was a marked negative relation of
Ab1-42 with CAMCOG scores above the change point
(rlm: t = -4.29, 178 df, P < 0.001), but no relation below it
(rlm: t = -1.17, 178 df, P = 0.24) (Table 2; Figure 2). Con-
gruent with this, Spearman’s rs showed a negative relation
only with CAMCOG scores above the change point (see
Table 2). The median and variance of Ab1-42 levels above
the change-point were greater than below it (median:
WMW P < 0.001; variance: F = 2.11; 92/100 df; P < 0.001).
In summary, the levels and variability of CSF Ab1-42 and
the slope of its relation with CAMCOG differed above and
below the change-point.
CSF Tau
CSF Tau levels showed monotonic but non-linear
dependence on CAMCOG scores with the change point
at a CAMCOG of 94. The change-point model fitted
better than the simple linear model (F = 5.39, 2/187 df,
P = 0.005). Tau levels related to CAMCOG scores more
strongly above the change-point (rlm: t = 2.01, 187 df,
Table 1 Demographic and clinical characteristics of the participants
Gender Age MMSE CAMCOG Follow-up (years)
Non-demented 48F: 47M 72.0 (66.0-78.8) 29 (28-30) 99 (81-106) 8.3 (4.7 12.9)
Alzheimer 60F: 37M 74.6 (69.7 79.8) 15 (9 23) 57 (10 96) 3.6 (1.4 6.2)
The values for Age, MMSE, CAMCOG and Follow-up are medians and inter-quartile ranges.
Table 2 Parameters of the CSF biomarkers and their relations to cognitive impairment, above and below their
change-points
CSF Biomarker Ab1-40 Ab1-42 Tau Phospho-Tau
Cf change-point Above Below Above Below Above Below Above Below
Median 5,052 3,937** 682 350** 259 568** 50 80**
Variance 3,857,482 1,854,983** 36,846 71,482** 176,946 73,418** 1,700 1,000**
Spearman’s r 0.21* -0.23* -0.24* -0.12 0.34** 0.28** 0.32** 0.16
Robust slope 93** -15** -0.048** -0.002 0.049* 0.004** 0.041** 0.004**
The values in the first row are the raw biomarker levels (pg/mL); the second row shows the variance of the median-standardised levels; the third row shows
Spearman’s rs for the rank correlations of biomarker levels with CAMCOG scores; the fourth row shows the slopes from the robust regressions of median-
standardised biomarker levels. For each biomarker, the “Above” and “Below” columns shows values for CAMCOG scores above and below the change-point,
respectively. Note that the correlations and slopes take cognitive impairment as the x-axis, which is the reverse of CAMCOG scores. Key:-
(*
): 0.10 >P > 0.05;
*: P < 0.01; **: P < 0.01. For medians and variances, probabilities refer to the comparison of values above and below the change-point; for Spearman’s r and
slopes they refer to comparison of values with zero.
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(Table 2; Figure 3). Spearman’s rs showed positive rela-
tions with cognitive impairment both above and below
t h ec h a n g ep o i n t( s e eT a b l e2 ) .T h em e d i a na n dv a r -
iance of CSF Tau levels in the CAMCOG range below
the change-point were much greater than above it (med-
ian: WMW P < 0.001; variance: F = 7.06; 119/73 df; P <
0.001). In summary, the levels and variability of CSF
Tau and the slope of its relation with CAMCOG dif-
fered above and below the change-point.
CSF phospho-Tau
CSF phospho-Tau levels showed monotonic but non-
linear dependence on CAMCOG scores, with the
change point at a CAMCOG of 93. The change-point
model fitted better than the simple linear model (F =
10.2, 2/187 df, P < 0.001). phospho-Tau levels related
directly to CAMCOG scores above the change-point
(t = 2.39, 187 df, P = 0.018), and below it (t = 2.48, 187
df, P = 0.014) (Table 2; Figure 4). The Spearman’s rs
showed a positive relation with cognitive impairment
only in the CAMCOG range above the change point
(see Table 2). The median and variance of CSF phos-
pho-Tau levels in the CAMCOG range below the
change-point were greater than above it (median:
WMW P < 0.001; variance: F = 2.82; 113/79 df; P <
0.001). In summary, the levels and variability of CSF
phospho-Tau and the slope of its relation with CAM-
COG differed above and below the change-point.
Discussion
CSF b-amyloid and Tau peptides showed distinctive
non-linear relationships with cognitive scores. These
relationships were strongest in the “normal” CAMCOG
r a n g ea n de v e r yb i o m a r k e r ’s change-point was near the
lower boundary of this range. These non-linearities are
inconsistent with a simple linear relationship between
central amyloid and Tau levels and cognitive impair-
ment which underlies the view that modulating central
amyloid and Tau may prevent cognitive decline in
dementia [37,38]. Instead, they suggest that most
changes in central amyloid and Tau precede the devel-
opment of clinical dementia [39].
Reliability of our findings
The findings of our change-point analyses are consistent
with published data. First, our re-analysis of data shown
in Figure 2 in Maruyama [19] shows a change-point in
the relationship between MMSE scores and CSF Ab1-42.
This resembles our present finding (see our Figure 2) in
that there is no relation between MMSE and Ab1-42
across MMSE scores below 20 (t = 0.21, NS), but a sig-
nificant relation across MMSE scores above 20 (t =
2.08, 76 df, P = 0.041). Second, our findings that
relations between CSF biomarkers and CAMCOG were
weak or absent below the change-points parallel the
observations of Vemuri [40] in AD patients; the stron-
ger relations that we found above the change-points
may also parallel Vemuri’s report [40] that biomarker
levels differed in their Controls and people with MCI.
Third, our finding of an inverted-U relation between
Ab1-40 and CAMCOG scores parallels the report that
Ab1-40 levels were high in MCI patients who progressed
to AD [21]. Additional factors that strengthen our
change-point results are (a) the strong resemblance
between the change-point-based robust regression mod-
e l sa n dt h em o d e l - f r e eL o w e s sf i t s( s e eF i g u r e s1 ,2 ,3 ,
4); (b) the similarity of the change-points (in absolute
CAMCOG scores) over all four biomarkers, despite the
different forms of each biomarker’s relation with cogni-
tive function; (c) the significant differences between the
variability and overall levels of the biomarkers on each
side of the change-points. Overall, therefore, the
change-points we describe are unlikely to be artefactual
and relations between CSF biomarkers and cognition
are probably non-linear.
The change-points that we defined are near the bot-
tom of the range of CAMCOG scores in our non-
demented volunteers. Hence, our findings are consistent
with many previous reports of higher levels of CSF Tau
moieties and lower levels of CSF amyloid moieties in
AD [22,25,41,42]. However, we prefer our change-point
categories to the diagnostic classification because they
derive from a model-free method, whereas the definition
of Alzheimer’s disease can vary [43,44]. Moreover, our
results indicate that neither the diagnostic classification,
nor the diagnostically agnostic linear regression fully
describes the relations between cognitive function and
C S Fb i o m a r k e r s .F i g u r e s1 ,2 ,3 ,4e a c hs h o wt h ef o u r
models that assume that the relations between CSF bio-
marker levels and cognitive function are either (a) sim-
ply linear (green dotted lines) or (b) simply categorical
(blue dot-dash lines). In each case these simple relations
fit the data quite well, but the non-linear relations based
on the change-point analyses (c - black solid lines) fit
better and more closely resemble the model-free robust
Lowess fits (d - red dashed lines). These improvements
in fit are not large, but their theoretical importance out-
weighs their actual size, as we discuss below.
CSF Ab1-40
CSF Ab1-40 showed biphasic dependence on cognitive
scores (Figure 1), with maximal levels near the lower
limit of our non-demented participants’ CAMCOG
scores. This is consistent with the findings that MCI
p a t i e n t sw h op r o g r e s s e dt oA Dh a dh i g hC S FA b1-40
[21] and CSF BACE activity is higher in MCI than in
either controls or AD patients [22]. It also fits with
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[24]. Zhong et al. [22] interpreted their findings as sup-
porting the amyloid cascade hypothesis. However, the
biphasic relationship of Ab1-40 admits at least two other
overlapping interpretations. First, it is consistent with
Combrinck’s hypothesis [25] that a pathogenic mechan-
ism may ‘burn out’ early in AD. Second, it is consistent
with the hypothesis that Ab may be protective [45,46],
and AD occurs only when pathogenic mechanisms over-
whelm the amyloid response. Further studies are neces-
sary to explore these three possibilities.
CSF Ab1-42
CSF Ab1-42 showed an overall inverse relationship with the
degree of cognitive impairment (Figure 2). This fits with
many reports of low Ab1-42 in AD patients [40-42]. Our
findings extend those reports by showing that Ab1-42
depends on cognitive level only in the range of non-
demented volunteers’ CAMCOG scores, not in the
patients’ range. The absence of any relation between CSF
Ab1-42 and CAMCOG scores below the change-point (in
the patient range) mirrors the recent report of Vemuri
et al. [40]. Together, these results indicate that low Ab1-42
may provide an early marker of likely progression to AD,
rather than an index of the severity of pathology in estab-
lished AD. The contrast between the monotonic relation
of Ab1-42 with cognitive level and the biphasic relation of
Ab1-40 is striking (compare Figures 1 and 2). This contrast
fits with observations that a low ratio of Ab1-42/Ab1-40
associates with imminent risk of mild cognitive impair-
ment and Alzheimer’s disease [47-49]. Together, these
findings highlight a need for further studies to explain why
the ratio of Ab1-42/Ab1-40 may vary [50].
CSF Tau and phospho-Tau
We found high CSF Tau moieties in AD patients [51].
Our results extend earlier reports by showing that, like
Ab1-42, Tau and phospho-Tau levels relate to CAMCOG
mainly above the change-point (in the non-demented
range of scores). Again, paralleling Vemuri et al.’sr e p o r t
[40], we found no simple relation between CSF phospho-
Tau and CAMCOG scores below the change-point, in
the patient range (Figures 3, 4). Together, these results
reinforce the view that phospho-Tau may provide an
early marker of likely progression to AD, but not an
index of the severity of pathology in established AD. The
findings that Ab1-42 and phospho-Tau show opposite
relations with cognitive scores within the non-demented
range fits with reports that the ratio of Ab1-42/Tau may
be a sensitive indicator of progression to AD [41,52,53].
Heteroscedasticity and measurement technicalities
The variances of the CSF biomarkers differed above and
below their change-points. The simplest explanation of
this is that the variance related to the mean, as often
occurs in biological variables. It may also represent indi-
vidual differences [54], or variations in pathogenic pro-
cesses or cognitive profiles [55]. For example, the
heteroscedasticity may possibly relate to ApoE status.
We did not test relations of ApoE alleles with change-
points, since we had no ap r i o r ihypothesis about this.
Further studies should address this potentially important
possibility. Whatever its explanation, the heteroscedasti-
city in every biomarker indicates a need for caution
when interpreting biomarker levels in patient and con-
trol groups, or in individuals [56]. For now, we note
that our use of highly robust linear modelling with a
breakdown point of 0.5 [36] guards against potential
bias in our analyses due to heteroscedasticity.
We collected CSF samples in polystyrene tubes and
stored them in polypropylene tubes. Both kinds of tube
can adsorb large amounts of biomarker molecules
[57,58]. If such adsorption saturates asymptotically, and
so depends non-linearly on initial biomarker concentra-
tion, then this might possibly contribute to both the
heteroscedasticity and the non-linear relations between
biomarker levels and cognitive function that we found.
However, we think this unlikely, as follows. If adsorption
of biomarkers tends to cause floor effects in their appar-
ent levels, then cognitive function might relate to bio-
marker levels only when they exceed this artefactual
floor. Such floor effects could possibly explain our find-
ing that CAMCOG scores did not relate to Ab1-42 in
the patient range of CAMCOG scores (because Ab1-42
levels are lowest in this range and so most susceptible
to adsorption-mediated floor effects). However, it cannot
simultaneously explain the inverted-U biphasic relation
of CAMCOG with Ab1-40; nor can it explain the direct
relationships of the CAMCOG scores with tau and
p-tau in the non-demented range of CAMCOG scores
(where lower Tau/p-Tau levels are potentially more sus-
ceptible to adsorption-mediated floor effects). Even for
Ab1-42, this account appears tenuous, in view of Bjerke’s
observation that detergent treatment released similar
percentages of Ab1-42 from adsorption in both control
and patient samples [57]. In summary, we think it unli-
kely that measurement technicalities can account for the
non-linear dependence of CSF biomarkers on cognitive
function that we observed.
We related CSF biomarker levels to raw CAMCOG
scores. Hence, apparent non-linearities in the relation-
ships may in part reflect non-linearities in the metric
properties of the CAMCOG (for example [59]). In parti-
cular, the narrow range of CAMCOG scores above the
change-points may contribute to the differences in the
slopes of their relations with biomarkers, since CAM-
COG scores here may relate less strongly to true cogni-
tive ability. However, this cannot account for (a) the
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nor for (b) the differences in Spearman’sr a n kc o r r e l a -
tion coefficients (which is independent of the metric)
for biomarkers and CAMCOG scores above and below
the change-points; nor for (c) the differences in variance
of biomarkers above and below the change-points.
Therefore, while the slopes of the relationships that we
found on each side of the change-points may vary under
non-linear transformations of the CAMCOG scores, it
seems unlikely that our use of raw CAMCOG scores
can account for the existence of the change-points.
Use of CAMCOG scores as metric for dementia
The main limitation of our change-point analyses is that
they used only cross-sectional data. Their use of CAM-
COG scores as the metric for dementia removes time
from the analysis of progression. The absolute cognitive
level is clinically meaningful regardless of age or the
duration of symptoms. Therefore, using it as the metric
for progression of pathological mechanisms may be pre-
ferable to using time. We know that individuals’ CAM-
COG scores can decline over time through the normal
and patient ranges [59]. Hence, it is tempting to view
the cross-sectional dependence of CSF biomarkers on
CAMCOG scores as a model of an individual’sl i k e l y
progression over time. However, the heteroscedasticity
that we observed (see above) means that individuals
might show important variations from this model. Con-
sequently, it would be inappropriate at this stage to con-
clude that the non-linear cross-sectional relationships
that we observed can indicate which non-demented peo-
ple will progress to AD, or which AD patients will
decline faster. Conversely, the cognitive stability of many
non-demented participants implies that the cross-
sectional relations of CSF biomarkers with their cogni-
tive function may index long-term adaptations to factors
that pre-dispose to AD [60]. Alternatively, these cross-
sectional relationships may reflect Vemuri et al.’s[ 4 0 ]
observation that levels of biomarkers differed between
controls and MCI groups, since we did not distinguish
these. MCI may be stable, remit, or progress to AD
[17,18]. Hence, the cross-sectional relations of biomar-
kers with CAMCOG scores in the non-demented range
may reflect a mix of long-term adaptations and of vul-
nerabilities to progression. Further longitudinal studies
relating CSF biomarker levels to cognitive function are
necessary to define more precisely the links between
CSF biomarkers and the putative primary pathogenic
processes of AD.
Generalizabilty
The generalizabilty of our study may be comparable
with other reports of CSF biomarkers. Participants in all
such studies are partly self-selected, both for entry to
the cohort and for consenting to LP. OPTIMA is a con-
venience cohort from a relatively small geographical
area in and around Oxford. Our study group was rela-
tively homogeneous and most non-demented volunteers
were cognitively stable, with few converting to AD,
despite our long follow-up. Together, these two consid-
erations indicate that our study group is unlikely to
be representative of the general population. Even so,
the consistency of our results with previous reports,
both with regard to differences in CSF biomarkers
between patients and non-demented controls and to
non-linearity [cf. [21-24]], even in a Japanese sample
[19], implies that our findings may reflect general phe-
nomena. Two further aspects of our study may improve
its generalizability. First, we confirmed the diagnosis of
AD and excluded non-Alzheimer dementias via neuro-
pathological examination in most patients (though peo-
ple who consent to autopsy are non-representative of
the general population [61]). Second, we related
CSF biomarker levels directly to cognitive scores. Neu-
ropathological designations and cognitive test scores
may provide a firmer basis for generalization than
clinical diagnoses, whose boundaries are uncertain
[16-18,43,44]. Overall, then, our study compares favour-
ably with other reports in this field.
Conclusions
The change-points in relation between cognitive func-
tion and all biomarkers were in the “normal” range of
CAMCOG scores. This is consistent with increasing
evidence that many non-demented older people have
some AD pathology [3-5], which implies that disease-
modifying treatments may be maximally effective for
prophylaxis before clinical dementia occurs [6,62].
Hence our results could help explain recent reports
that anti-amyloid treatments, such as tarenflurbil and
anti-amyloid immunotherapy, had no effect in estab-
lished AD [63-65], assuming that these treatments had
anti-amyloid effects at the doses tested. The biphasic
relationship we observed for Ab1-40 is also consistent
with the possibility that it may contribute to neuronal
protection or maintenance [45,60,66,67]. If this were
ultimately to prove to be the case, then BACE inhibi-
tion at critical stages might be detrimental. Whereas
the field focuses most on Ab1-42, this possibility sug-
gests that more attention should be given to under-
standing the physiological role(s) of Ab1-40.
Additional material
Additional file 1: Supplementary methods. A document outlining
additional diagnostic considerations.
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